Antibiotic therapies for clostridioides difficile infection in children

Anne J. Gonzales-Luna, Travis J. Carlson, Kevin W. Garey

Producción científica: Articlerevisión exhaustiva

1 Cita (Scopus)


While rates of Clostridioides difficile infection (CDI) are increasing among children in the United States, studies assessing CDI treatment in children are severely lacking. Thus, treatment guidelines have historically relied on evidence from limited observational data in children and randomized controlled trials (RCTs) conducted in adults to form recommendations. Currently, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend metronidazole and/or vancomycin for pediatric CDI depending on disease severity. Recently however, the first and only RCT of CDI treatment in children demonstrated fidaxomicin to be non-inferior to vancomycin, proving its safety and efficacy in this population. Additionally, observational data published since the IDSA/SHEA guidelines were released suggest metronidazole has lower rates of clinical improvement when compared to vancomycin in hospitalized children with non-severe CDI. Given these recent publications, fidaxomicin and vancomycin, instead of metronidazole, appear to be more appropriate, evidence-based options for the treatment of CDI in children.

Idioma originalEnglish (US)
Páginas (desde-hasta)S52-S57
PublicaciónJournal of the Pediatric Infectious Diseases Society
EstadoPublished - nov 1 2021
Publicado de forma externa

ASJC Scopus subject areas

  • General Medicine


Profundice en los temas de investigación de 'Antibiotic therapies for clostridioides difficile infection in children'. En conjunto forman una huella única.

Citar esto